Patent ID: 9090683
Filing Date: 2015-07-28
Classification: A61K,A61P,C07D,C07K,G01N

Abstract:
1. A method of detecting, diagnosing, or monitoring cancer in a subject, the method comprising the steps of (a) contacting cells of the subject with an anti-DLL3 antibody, wherein the anti-DLL3 antibody comprises residues 24-34 of SEQ ID NO: 96 for CDR-L1, residues 50-56 of SEQ ID NO: 96 for CDR-L2, residues 89-97 of SEQ ID NO: 96 for CDR-L3, residues 31-35 of SEQ ID NO: 97 for CDR-H1, residues 50-65 of SEQ ID NO: 97 for CDR-H2 and residues 95-102 of SEQ ID NO: 97 for CDR-H3, wherein the residues are numbered according to Kabat; and (b) detecting the anti-DLL3 antibody on cancer cells.